Top Midday Stories: UnitedHealth Under DOJ Investigation Over Medicare Billing Practices; Novo Nordisk Resolves Ozempic Shortage

MT Newswires Live
02-22

All three major US stock indexes were down around midday trading on Friday as weak consumer sentiment data weighed on markets.

In company news, UnitedHealth Group (UNH) is under investigation by the US Department of Justice for allegedly encouraging doctors to record diagnoses that result in extra payments to the insurer's Medicare Advantage plans, The Wall Street Journal reported Friday, citing people familiar with the matter. In the Medicare Advantage system, insurers receive lump-sum payments from the federal government to administer enrollee's Medicare benefits, and when patients have certain diagnoses, the payments go up, creating an incentive to diagnose more diseases, according to the report. UnitedHealth shares were down 9% around midday.

Novo Nordisk (NVO) has resolved its shortage of weight-loss drugs Ozempic and Wegovy, according to an update on the US Food and Drug Administration website. The resolved shortage issue means other companies, like Hims & Hers (HIMS), will no longer be legally allowed to produce and sell compounded alternatives. Novo Nordisk shares were up 5.8%, while those of Hims & Hers were down 21%.

The DOJ and the US Securities and Exchange Commission are investigating a $32 million deal between CrowdStrike Holdings (CRWD) and Carahsoft to provide cybersecurity tools to the Internal Revenue Service, Bloomberg reported Friday, citing two people familiar with the matter and a document it saw. Carahsoft paid CrowdStrike for the deal, but the IRS never bought the products, Bloomberg first reported in October 2024. CrowdStrike shares were down 2.9%.

Rivian Automotive (RIVN) reported a Q4 loss late Thursday of $0.70 per diluted share, narrowing from a loss of $1.58 a year earlier and less of a loss than the $0.77 expected by analysts surveyed by FactSet. Fourth-quarter revenue was $1.73 billion, up from $1.32 billion in the year-ago period and above the FactSet consensus analyst estimate of $1.40 billion. The automaker said it expects to deliver 46,000 to 51,000 vehicles in 2025, down from 51,579 deliveries in 2024. Rivian shares were down 3.5%.

Coinbase (COIN) said Friday the US SEC agreed in principle to withdraw its enforcement case against the company, pending commissioner approval. Coinbase shares were down 0.7%.

bluebird bio (BLUE) said Friday it has agreed to be acquired by funds managed by the Carlyle Group (CG) and SK Capital Partners. Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending on Dec. 31, 2027. Shares of bluebird were down 38%, while those of Carlyle were down 2%.

Alphabet's (GOOG) Google is facing charges from the European Union for allegedly breaching Digital Markets Act rules after proposed changes to its search results failed to address regulators' and rivals' concerns, Reuters reported Friday, citing people with direct knowledge of the matter. The European Commission has been probing Google for potential breaches of the DMA since March 2024, according to the report. Alphabet shares were down 1.8%.

Apple (AAPL) is removing Advanced Data Protection, its most advanced end-to-end encrypted security feature for cloud data, in the UK following a government order to build a backdoor for accessing user data, Bloomberg reported Friday, citing a company statement. Apple shares were up 0.5%.

Price: 457.65, Change: -44.77, Percent Change: -8.91

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10